Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
WESTON, Fla., May 14, 2024 /CNW/ - Apotex Corp. announced today the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States.
Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
"This launch provides American women access to affordable fertility treatments," said Christine Baeder, President, Apotex Corp. "It demonstrates our unwavering focus on meeting patient needs with high-quality medication that is more accessible to everyone."
Please refer to the complete Prescribing information here for information on Warnings and Precautions, Adverse Reactions and Contraindications.
About Apotex Corp.
Apotex Corp. is a US-based company that sells high-quality, affordable and complex medicines to patients in the United States. Headquartered in Weston, Florida, Apotex Corp. and its global affiliates are committed to supplying patients with an integrated portfolio of generic, biosimilar and innovative branded pharmaceutical products.
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....
